All studies
Gastroenterology · Claims + National Database · US, France

Kirchgesner 2021

Crohn's disease

Not definedSuperiorityAcademia2/5 disclosures
Comparisons
1
In the analysis
0
1 withheld
Target trials
1
Emulations reported
3
2 treatments

Comparisons

1 shown
Randomized trialEmulation
Outcome & target trialTrial vs emulationOn a shared scaleAgreement
Treatment failure, 26 weeks
vs SONIC·RR·Efficacy
0.780.62–0.97
0.710.62–0.82
not pooled

Design and methods

Estimand
Not defined
Design hypothesis
Superiority
Matching / weighting
1:1 PS matching
Analysis method
Log-binomial regression
Missing data
Complete case
Covariates adjusted
27
DAG
No
QBA
No

Data and sample

Data type
Claims + National Database
Data sources
3
Geography
US, France
Eligible sample
15007
Treated
1437
Control
1437
Emulations
3
Treatments compared
2

Transparency

2/5
Protocol
No pre-registration
Preprint
No preprint
Conference abstract
https://dx.doi.org/10.1002/pds.5305
Data availability
Unavailable
Code availability
Unavailable
Conflicts of interest
Declared: Industry
COI institutions
Roche, Pfizer, Janssen, Allergan, AbbVie, Merck Sharp & Dohme, Ferring Pharmaceuticals, Mayoly-Spendler, Takeda, Tillots, Abbott, Hospira-Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb
Funding
Declared: Research institute
Funders
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School

The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.

Provenance

Review key
2021_Kirchgesner_CrohnsDisease
DOI
https://doi.org/10.1002/cpt.2304
Affiliations
Harvard Medical School, Sorbonne Université
Sector
Academia
Target trials (study level)
SONIC
Registration
NCT00094458